Terje R. Pedersen

Medicine · Health Sciences

86h-index69.3kcitations248works55.52yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lipoproteins and Cardiovascular Health(171), Health Systems, Economic Evaluations, Quality of Life(61), Diabetes, Cardiovascular Risks, and Lipoproteins(42), Cardiac Valve Diseases and Treatments(36), Pharmaceutical Economics and Policy(34)

Publications245 total

The role of relatives in e-governance access among elderly citizens: vignettes from the Danish Covid-19 vaccination
Edward Elgar Publishing eBooks·2025Open Access
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials
The Lancet·2022· 222 citedOpen Access
Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects　― A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial ―
Circulation Journal·2021· 46 citedOpen Access
LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial
Atherosclerosis·2021· 19 citedOpen Access
Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project
Atherosclerosis Supplements·2020· 38 citedOpen Access
Abstract 16688: Effects of Evolocumab in Patients With Prior Percutaneous Coronary Intervention: An Analysis From the Fourier Trial
Circulation·2020
Abstract 14770: Reduction With Evolocumab in Complex Coronary Disease Requiring Revascularization: Insights From the FOURIER Trial
Circulation·2020· 3 cited
Abstract 13200: Relationship Between Baseline Low-Density Lipoprotein Cholesterol and Percent Low-Density Lipoprotein Cholesterol Reduction With Evolocumab in the FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk) Trial
Circulation·2020
Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy
JAMA Cardiology·2020· 81 citedOpen Access
2019 ESC/EAS Guidelines for themanagement of dyslipidaemias: lipid modification to reduce cardiovascular risk
Russian Journal of Cardiology·2020· 292 citedOpen Access
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction
JAMA Cardiology·2020· 88 citedOpen Access
Cognition After Lowering LDL-Cholesterol With Evolocumab
Journal of the American College of Cardiology·2020· 87 cited
Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction
JAMA Cardiology·2020· 30 citedOpen Access
An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial
JAMA Cardiology·2020· 124 citedOpen Access
Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis
Stroke·2020· 174 citedOpen Access
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism
Circulation·2020· 99 citedOpen Access
LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial
European Journal of Preventive Cardiology·2020· 101 cited
Wytyczne ESC/EAS dotyczące postępowania w dyslipidemiach: jak dzięki leczeniu zaburzeń lipidowych obniżyć ryzyko sercowo‑naczyniowe (2019)
Kardiologia Polska·2020· 1 citedOpen Access
Wytyczne ESC/EAS dotyczące postępowania w dyslipidemiach: jak dzięki leczeniu zaburzeń lipidowych zmniejszyć ryzyko sercowo‑naczyniowe (2019). Dane uzupełniające
Kardiologia Polska·2020Open Access
ESC/EAS 2019 Guidance on the Treatment of Dyslipemias: Lipid Modification to Reduce Cardiovascular Risk
Revista Española de Cardiología·2020· 1 cited
page 1 of 13Next →

Frequent Co-authors

Anthony Keech(16), John Kjekshus(15), Anders Olsson(15), Marc S. Sabatine(14), Robert P. Giugliano(12), Sabina A. Murphy(8), Peter Sever(8), Kalevi Pyörälà(8), Armando Lira Pineda(8), Antonio M. Gotto(7), Ole Færgeman(7), Helen M. Colhoun(7), Paul M. Ridker(7), John J.P. Kastelein(7), Victoria Delgado(6), Borislava Mihaylova(6), Gabriele Riccardi(6), Marja‐Riitta Taskinen(6), Olov Wiklund(6), Narimon Honarpour(6)